Last reviewed · How we verify
NCT03251352: TFR_china
TKI Discontinuation in CML Patients of China
trial in Leukemia in 98 participants. Status unknown.
30 September 2022
Quick facts
| Lead sponsor | Shenzhen Second People's Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 98 |
| Start date | 1 March 2017 |
| Primary completion | 30 September 2022 |
| Estimated completion | 30 October 2022 |
| Sites | 1 location across China |
Conditions studied
- Leukemia — all drugs for Leukemia →
- Myelogenous — all drugs for Myelogenous →
- Chronic — all drugs for Chronic →
- BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) — all drugs for BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) →
Sponsor
Shenzhen Second People's Hospital
Who can join
18 and older, any sex, with Leukemia or Myelogenous. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to describe the maintenance of the molecular remission after tyrosine kinase inhibitor (TKI) disconnection in chronic myeloid leukaemia (CML) patients in China in the real-world clinical practice setting. This is a post-marketing, non-interventional, single-arm, prospective registry study in adult patients with chronic phase (CP) and accelerated phase (AP) in China. Patients will be recruited consecutively from the study sites during the enrollment period. The enrolled patients will be undertaking TKI discontinuation under the conditions of informed consent and frequent monitoring according to the clinical guideline.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03251352
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Leukemia
Currently open trials in the same condition.
- NCT07405424 — Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia · NA · recruiting
- NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting
Other Shenzhen Second People's Hospital trials
Trials by the same sponsor.
- NCT06542016 — An Evaluation of the KCCQ Score in Predicting Cardiovascular Risk in Dialysis Patients · recruiting
- NCT05540808 — The Value of Full-targeted Pathogen Capture Metagenomics Next Generation Sequencing in Etiological Diagnosis of Sepsis · unknown
- NCT05603975 — Analgesic Effect of Esketamine in DCSB in Adultscontrolled Study · NA · unknown
- NCT05465980 — Development and Validation of the Prediction Model for Cognitive Impairment · unknown
- NCT05452759 — Research of Spiral Exhalation Device Oxygen Therapy to Improve the Treatment Effect of Patients With Severe Pneumonia · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03251352 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Second People's Hospital
- Last refreshed: 16 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03251352.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing